Pariani N, et al. - Researchers investigated the type, frequency, and course of thyroid dysfunction (TD) in a cohort of alemtuzumab-treated patients with multiple sclerosis (MS) in the UK. They reviewed case records of alemtuzumab-treated patients who developed TD. They found that Graves disease (GD) occurred frequently in these patients and required definitive or prolonged antithyroid drug (ATD) treatment; this finding was contrary to published literature. In addition, changing activity of TSH receptor antibody (TRAb) was indicated by fluctuating thyroid status in GD and unexpectedly high frequency of TRAb-positive hypothyroidism. In these patients, both blocking and stimulating TRAb has been reported.